Celltrion, Inc. (068270.KS)
- Previous Close
190,300.00 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 241,000.00 - Volume
0 - Avg. Volume
596,928 - Market Cap (intraday)
39.66T - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Aug 12, 2024 - Aug 16, 2024
- Forward Dividend & Yield 500.00 (0.26%)
- Ex-Dividend Date Dec 27, 2023
- 1y Target Est
229,929.00
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 3 clinical trial; CT-P17 for the treatment of autoimmune diseases which is in phase 3 clinical trial; CT-P16 for the treatment of non-small cell lung cancer and colon cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 3 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P47 for the treatment of rheumatoid arthritis, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. The company was founded in 2002 and is headquartered in Incheon, South Korea.
www.celltrion.comRecent News: 068270.KS
Performance Overview: 068270.KS
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 068270.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 068270.KS
Valuation Measures
Market Cap
39.66T
Enterprise Value
40.91T
Trailing P/E
70.62
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
17.07
Price/Book (mrq)
2.35
Enterprise Value/Revenue
17.66
Enterprise Value/EBITDA
49.23
Financial Highlights
Profitability and Income Statement
Profit Margin
16.96%
Return on Assets (ttm)
2.30%
Return on Equity (ttm)
3.70%
Revenue (ttm)
2.32T
Net Income Avi to Common (ttm)
392.83B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
920.51B
Total Debt/Equity (mrq)
12.82%
Levered Free Cash Flow (ttm)
-1.53T